Clinical trial
Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
NCT01492361 is registered in ClinicalTrials.gov with Amarin Pharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)
- Lead sponsor
- Amarin Pharma Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- May 31, 2018
- Enrollment
- 8,179 (actual)
- Sites
- 410
Conditions
As the registry lists them; a condition with its own page is linked.